Overview

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Status:
Not yet recruiting

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.

Phase:

Phase 2

Details

Lead Sponsor:

University of Alabama at Birmingham

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Carboplatin